Furthermore, the employment of T cell based therapies induces loss-of-function mutations in critical signaling pathways that promote antigen presentation and T cell function, such as JAK1/2 and STAT1 mutations, to evade IFN-γ stimulation and impair T cell function in melanoma patients post anti-PD-L1 and anti-CTLA-4 [107]. This evidence concerns the gene CD274 and melanoma.